ZA946475B - Smooth muscle cell migration inhibition - Google Patents

Smooth muscle cell migration inhibition

Info

Publication number
ZA946475B
ZA946475B ZA946475A ZA946475A ZA946475B ZA 946475 B ZA946475 B ZA 946475B ZA 946475 A ZA946475 A ZA 946475A ZA 946475 A ZA946475 A ZA 946475A ZA 946475 B ZA946475 B ZA 946475B
Authority
ZA
South Africa
Prior art keywords
pct
smooth muscle
cell migration
muscle cell
migration inhibition
Prior art date
Application number
ZA946475A
Other languages
English (en)
Inventor
Suresh Babuhai Chahwala
Derek Paul Winslow
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10741080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA946475(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of ZA946475B publication Critical patent/ZA946475B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA946475A 1993-08-26 1994-08-25 Smooth muscle cell migration inhibition ZA946475B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939317773A GB9317773D0 (en) 1993-08-26 1993-08-26 Therapeutic compound

Publications (1)

Publication Number Publication Date
ZA946475B true ZA946475B (en) 1996-02-26

Family

ID=10741080

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA946475A ZA946475B (en) 1993-08-26 1994-08-25 Smooth muscle cell migration inhibition

Country Status (20)

Country Link
US (1) US6080761A (xx)
EP (1) EP0754043B1 (xx)
JP (2) JP3007992B2 (xx)
KR (1) KR0163840B1 (xx)
CN (1) CN1060039C (xx)
AT (1) ATE192337T1 (xx)
AU (1) AU686658B2 (xx)
CA (1) CA2170278C (xx)
DE (1) DE69424317T2 (xx)
DK (1) DK0754043T3 (xx)
ES (1) ES2145149T3 (xx)
GB (1) GB9317773D0 (xx)
GR (1) GR3033547T3 (xx)
IL (1) IL110700A (xx)
NO (1) NO308826B1 (xx)
NZ (1) NZ271993A (xx)
PT (1) PT754043E (xx)
TW (1) TW470646B (xx)
WO (1) WO1995005822A1 (xx)
ZA (1) ZA946475B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
GB0020842D0 (en) * 2000-08-23 2000-10-11 Pfizer Ltd Therapeutic compositions
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
EP1345901A2 (en) * 2000-12-29 2003-09-24 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
CN1152013C (zh) * 2001-11-22 2004-06-02 张喜田 一类左旋氨氯地平盐的水合物及其制剂
BRPI0511095B8 (pt) * 2004-10-20 2021-05-25 Emcure Pharmaceuticals Ltd um processo para produção de enantiômero de anlodipino em alta pureza ótica
KR100828883B1 (ko) * 2006-10-27 2008-05-09 씨제이제일제당 (주) 라세믹 암로디핀으로부터 ｓ-(-)-암로디핀의 분리방법
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804630D0 (en) * 1988-02-27 1988-03-30 Pfizer Ltd Preparation of r-& s-amlodipine
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine

Also Published As

Publication number Publication date
DE69424317T2 (de) 2000-08-24
NO308826B1 (no) 2000-11-06
TW470646B (en) 2002-01-01
KR960703593A (ko) 1996-08-31
JP3007992B2 (ja) 2000-02-14
CA2170278A1 (en) 1995-03-02
NO960730L (no) 1996-02-23
EP0754043B1 (en) 2000-05-03
NZ271993A (en) 1997-11-24
IL110700A0 (en) 1994-11-11
GR3033547T3 (en) 2000-09-29
IL110700A (en) 1999-04-11
AU686658B2 (en) 1998-02-12
ES2145149T3 (es) 2000-07-01
JPH08509004A (ja) 1996-09-24
US6080761A (en) 2000-06-27
ATE192337T1 (de) 2000-05-15
JP2000044475A (ja) 2000-02-15
CN1060039C (zh) 2001-01-03
PT754043E (pt) 2000-09-29
DK0754043T3 (da) 2000-08-07
AU7612994A (en) 1995-03-21
EP0754043A1 (en) 1997-01-22
GB9317773D0 (en) 1993-10-13
KR0163840B1 (ko) 1998-12-01
CN1129907A (zh) 1996-08-28
CA2170278C (en) 1999-08-03
NO960730D0 (no) 1996-02-23
WO1995005822A1 (en) 1995-03-02
DE69424317D1 (de) 2000-06-08

Similar Documents

Publication Publication Date Title
GR3029405T3 (en) COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A -g(b)-LACTAM CHOLESTEROL ABSORPTION INHIBITOR.
ZA969880B (en) Flame inhibitor composition and method of application
ZA946475B (en) Smooth muscle cell migration inhibition
HK1011940A1 (en) A method of treating endo-osteal materials
ZA905937B (en) Calcium hypochlorite compositions for inhibiting scale formation and a method for their use
EP0553674A3 (en) Method of item selection for computerized adaptive tests
EP0783283A4 (en) METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE
HU9301272D0 (en) Method for treating inflammations and wounds using plasminogene activator inhibitors
EP0651766A4 (en) INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
HU9603607D0 (en) Method and prophylaxis of osteoporosis
EP0736579A3 (en) Rust treatment method and rust inhibiting coating composition for steel plate
PL327600A1 (en) Method of treating depressions
EP0682091A3 (en) Composition for treating a surface and a method for protecting the surface of building materials against undesirable reactions by microorganisms.
PL326294A1 (en) Method of retarding the inhibitor 1 of plasminogene activator
ZA948721B (en) A method of treating coronary thrombosis
EP0692965A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS
EP0451436A3 (en) Method of curing and preventing obesity by alpha-amylase inhibitor
NO953480L (no) Anvendelse av, og metode ved behandling som anvender, carbazolyl-(4)-oksypropylamin-forbindelser for inhibering av glatt-muskelcelle-formering
GB9301720D0 (en) Method and compositions for treating anoestrus
ZA967392B (en) A method of treating timber
AU5051090A (en) A method of treatment or prevention of post-PTCA restenosis by post-PTCA restenosis inhibitor
HUT76404A (en) Method for controlling cycles of events in time
AU7812691A (en) Method of nitriding steel